Sci PharmtechTPE:4119 +1.24%67 Gross Margin % is 28.02% as of Dec. 2025, which is 11% below its 10-year median of 31.39. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$96.56 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 936 Drug Manufacturers companies, Sci Pharmtech ranks worse than 85.79% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sci Pharmtech had a gross margin of 28.02% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sci Pharmtech Gross Margin % Related Terms
Sci Pharmtech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sci Pharmtech (TPE:4119) has a Gross Margin % of 28.02% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sci Pharmtech and its competitors. This is 11% below median its historical median of 31.39. Over the past decade, Sci Pharmtech's Gross Margin % has ranged from 24.08 to 47.39. According to the industry distribution chart, Sci Pharmtech ranks #803 out of 936 companies in the Drug Manufacturers industry, placing it in the top 85.8%.
Is Sci Pharmtech's Gross Margin % too high?
Sci Pharmtech's current Gross Margin % of 28.02% is 11% below median its 10-year median of 31.39. Over the past 10 years, this metric has ranged from a low of 24.08 to a high of 47.39. The Drug Manufacturers industry median Gross Margin % is 48.50. Sci Pharmtech's value of 28.02% is 42.2% below this industry median. Based on the distribution chart, Sci Pharmtech ranks #803 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #803 out of 936 companies for Gross Margin %. This places Sci Pharmtech in the lower half of its industry. The industry median Gross Margin % is 48.50. Sci Pharmtech's value of 28.02% is 42.2% below this benchmark. Historically, Sci Pharmtech's own Gross Margin % has ranged from 24.08 to 47.39 over the past decade. While the company's 10-year median is 31.39 vs. the industry median of 48.50, Sci Pharmtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current Gross Margin % of 28.02% is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current Gross Margin % is 28.02%, which is 11% below median its own 10-year median of 31.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.56, compared to a current price of NT$44.80 — trading 53.6% below its estimated fair value. The current Gross Margin % is 28.02%, which is 11% below median its 10-year median of 31.39 and 42.2% below the Drug Manufacturers industry median of 48.50. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Gross Margin % is 28.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$44.80 is trading 53.6% below its estimated GF Value™ of NT$96.56.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
Gross Margin %: 28.02% (11% below median its 10-year median of 31.39)
GF Value™: NT$96.56 vs. price of NT$44.80 (53.6% below fair value)
Industry Position: 42.2% below the Drug Manufacturers median (#803 of 936)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
